Sarah Williams

Sarah Williams currently serves as Director at adMare BioInnovations since June 2019, where previous roles included Senior Associate in Investments, Investment Analyst, Associate in Science & Business for Program Development and Partnerships, and Scientist within the same division. In addition to ongoing contributions at adMare, Sarah Williams holds positions as Board Observer for Abdera Therapeutics and Evolved Therapeutics. Prior experience includes roles at The Centre for Drug Research and Development, where contributions involved identifying and evaluating research projects, as well as positions in preclinical research and development at viDA Therapeutics, IonsGate Preclinical Services Inc., Cardiome Pharma Corp, and The University of British Columbia. Educational qualifications include a PhD in Physiology from the University of Adelaide and experience as a visiting graduate student at the University of Alberta specializing in vascular physiology.